For three consecutive years! Medicilon has been honored with the "Top Ten Drug Innovation Service Institutions of the Year" award at the 4th Pharmaceutical Innovation Awards.

On June 20^t^h, the 4^th Pharmaceutical Innovation Awards ceremony, organized by the Securities Times under People's Daily, was unveiled in Shanghai. Medicilon was honored with the "Top Ten Drug Innovation Service Institutions of the Year" at the 4^thPharmaceutical Innovation Awards for its innovative capabilities and service quality in the field of biopharmaceutical preclinical R&D services.

This marks the third consecutive year that Medicilon has won this prestigious award. This achievement not only serves as a profound recognition of its two decades of continuous contributions to drug development but also stands as the best testament to its spirit of innovation.

About Pharmaceutical Innovation Awards

The "Pharmaceutical Innovation Award" is a highly influential event within the industry, organized by Securities Times, an authoritative financial and securities media outlet under the People's Daily. The award aims to recognize companies and individuals who have made outstanding achievements in the field of pharmaceutical innovation, thereby promoting the enhancement of China's pharmaceutical innovation capabilities and industrial development. The selection process strictly adheres to principles of scientific rigor, fairness, and impartiality. It utilizes the "People's Financial • Innovative Drug Index" database and company application materials, and involves multiple stages such as expert reviews and public voting, ensuring that each awarded project, company, and individual truly deserves the recognition.

As one of the few one-stop preclinical research service platforms for biopharmaceuticals in China, Medicilon has a long-standing tradition of innovation. Since its establishment, Medicilon has always regarded innovation as its core driving force, continually creating and improving its service platform. This has enabled seamless integration from drug discovery and pharmaceutical research to preclinical research. Moreover, Medicilon has built cutting-edge research service platforms in advanced fields such as antibodies, peptides, ADCs, PROTACs, mRNA vaccines, small nucleic acid drugs, and cell and gene therapy (CGT).

With twenty years of innovative accumulation and rich experience, Medicilon precisely empowers its clients, helping them achieve numerous remarkable successes in the pharmaceutical field. As of the end of April 2024, Medicilon has been involved in the research and development of 480 new drug and generic drug projects that have received approvals from CFDA/NMPA, US FDA, and Australia's TGA to enter clinical trials. Among these, Medicilon has successfully assisted in the development of 34 antibodies (including monoclonal, bispecific, and trispecific antibodies), 24 ADC drugs, 8 GLP-1 hypoglycemic drugs, and 3 traditional Chinese medicines approved for clinical use. The successful development of these drugs not only provides patients with more treatment options but also injects strong momentum into the innovative development of the entire pharmaceutical industry. In addition, Medicilon actively serves over 50 ADC clients, more than 40 small nucleic acid clients, and over 3 PROTAC-related clients, providing them with professional technical support and solutions, earning widespread acclaim.

Medicilon's winning of the "Pharmaceutical Innovation Award" is a high recognition of its innovative spirit and professional strength. It also serves as a motivation and encouragement for its continuous efforts in promoting innovation and development within the pharmaceutical industry. This honor will inspire Medicilon to continue adhering to its innovation principles, increasing investment in research and development, strengthening technological innovation, and enhancing talent development. This commitment will continuously drive innovation and promote the advancement of the pharmaceutical industry. At the same time, Medicilon will also empower its clients with even more professional and efficient service quality, thereby contributing to the thriving development of the pharmaceutical industry!

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration. The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies, ADCs , mRNA vaccines , small nucleic acid drugs , PROTAC , and CGT technical service platform that have helped 421 INDs obtain clinical approval. It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

阅读全文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the preclinical study of the antibody-drug-conjugate (ADC) DXC005, including the pharmacology study , DMPK study and the safety evaluation . Medicilon has previously completed integrated preclinical research on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

阅读全文

Shanghai Medicilon Inc.

搜索此博客